AHA/ACC Guideline Updates: Risk Stratification and Management of Acute Pulmonary Embolism
USA: The first dedicated pulmonary embolism (PE) guideline from the American Heart Association (AHA) and American College of Cardiology (ACC) provides clinicians with an updated framework for evaluating, classifying, and managing acute PE in adults. Developed in collaboration with several major professional societies, the guideline introduces a five-category clinical classification system designed to better distinguish disease severity and support treatment decisions.
The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults was published in the Journal of the American College of Cardiology in February 2026. It represents the first dedicated AHA/ACC guideline focused specifically on PE.
Traditionally, PE has been categorized as low, intermediate, or high risk, with terminology varying between major guidelines. The new AHA/ACC Clinical Categories expand this framework to five groups, ranging from incidentally detected or asymptomatic PE to PE associated with hemodynamic instability. For patients with more severe disease, a respiratory modifier can further identify significant respiratory impairment, recognizing that PE can produce serious clinical consequences even when blood pressure remains preserved.
The guideline emphasizes individualized assessment using multiple clinical, laboratory, and imaging parameters rather than relying on a single marker of severity.
Key Recommendations:
- Rule out PE in appropriate patients: Among individuals with a clinical pretest probability below 50%, PE can be excluded using an age-adjusted D-dimer threshold, the YEARS criteria, or both.
- Use CT pulmonary angiography for diagnosis: CT pulmonary angiography is the preferred imaging modality. When it is contraindicated, ventilation–perfusion single-photon emission CT may be considered.
- Assess PE severity comprehensively: Classification should incorporate symptoms, validated clinical scores such as the simplified PE Severity Index, thrombus location, troponin levels, right ventricular dysfunction, evidence of transient or normotensive shock, overt hemodynamic instability, and respiratory status.
- Consider outpatient treatment for lower-risk disease: Patients with incidentally detected PE or without markers of severe disease may be candidates for home treatment or early discharge with a direct oral anticoagulant.
- Prefer low-molecular-weight heparin in hospitalized patients: For most hospitalized patients, low-molecular-weight heparin is preferred over unfractionated heparin.
- Consider reperfusion strategies in unstable PE: Mechanical thrombectomy and catheter-directed fibrinolysis are reasonable options for patients with hemodynamically unstable PE. Their role in less-severe disease remains uncertain.
- Consider extracorporeal support in refractory shock: Extracorporeal membrane oxygenation may be considered for patients with refractory cardiogenic shock.
- Use inferior vena cava filters selectively: Inferior vena cava filters may be appropriate when anticoagulation is absolutely contraindicated.
- Individualize extended anticoagulation: Treatment beyond 3–6 months should consider cancer status, transient or persistent risk factors for thrombosis, and bleeding risk.
The guideline also gives attention to post-PE management, including persistent symptoms, anticoagulation intensity, return to physical activity, and anxiety. This broader focus may help address issues that can persist after the acute episode has been treated.
Management of PE is expected to continue evolving as results from ongoing studies become available. Trials such as HI-PEITHO, PRAGUE-26, and PEITHO-3 may provide additional evidence regarding reperfusion strategies and risk-based treatment, potentially influencing future recommendations.
Reference:
Creager MA, et al. AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN guideline for the evaluation and management of acute pulmonary embolism in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2026 Feb 19; 2026:19; [e-pub]. DOI: 10.1016/j.jacc.2025.11.005.
Next Story